Invizius Limited, a Motherwell, Scotland, UK-based biotechnology company developing treatments to suppress unwanted innate immune responses, closed Series A financing of £5.3m.
The round was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. The Series A remains open to other investors until June 2021.
The company intends to use the funds to complete a First-in-Man safety study in 2022 of its H-Guard® Priming Solution to reduce the life-threatening inflammatory effects of haemodialysis.
Led by Richard Boyd, Chief Executive Officer, Invizius is a late pre-clinical-stage biotechnology company developing treatments to suppress unwanted innate immune responses, focused initially on reducing the life-threatening inflammatory effects of dialysis. Founded in 2017, the University of Edinburgh spin-out is developing its proprietary H-Guard® Priming Solution, comprising a novel protein that lines the inside of the dialysis filter and helps dialysis to take place undetected by the body’s immune system. This suppresses the blood’s foreign body response, thereby preventing a hostile inflammatory reaction.
The company, which has established the regulatory pathway in North America and the potential for coincident approval in Europe, is looking to expand its product pipeline into other, high-value indications.